FDA Biologics & Clinical Pipeline
Material regulatory developments from FDA CBER are tracked daily by Cresthaven Analytics. Over the last 90 days, 20 material briefs relevant to professionals operating in the healthcare & life sciences sector have been published below. Each brief is sourced directly from the primary regulatory feed, summarized for institutional readers, and scored for materiality.
Recent material activity
A selection of recent published briefs; this is not a complete archive.
FDA adds boxed warning to Adzynma for neutralizing antibody risk associated with fatal outcomes in cTTP patients
FDA issued a safety action on September 23, 2026 requiring a new boxed warning for Adzynma, a recombinant ADAMTS13 enzyme replacement therapy approved for congenital thrombotic thrombocytopenic purpura. The warning addre…
Read the full FDA Biologics & Clinical Pipeline brief →FDA warns NexCell Scientific over unlicensed umbilical cord blood cell product sold without approval
FDA's Center for Biologics Evaluation and Research issued a warning letter to NexCell Scientific Inc on September 11, 2026, following facility inspections in December 2025 and February 2026. The letter cites the company'…
Read the full FDA Biologics & Clinical Pipeline brief →FDA issues direct final rule permitting non-animal safety testing methods for human drugs and biologics
The FDA issued a direct final rule on September 21, 2026, clarifying that non-animal testing methods may be used where appropriate to assess drug and biologic safety before first-in-human trials. The rule formalizes regu…
Read the full FDA Biologics & Clinical Pipeline brief →FDA launches Expedited IND Pilot Program under HHS Operation TrialBlazer to accelerate first-in-human trials
FDA announced the Expedited Investigational New Drug Pilot Program on September 18, 2026, under HHS Operation TrialBlazer. The program tests new approaches to accelerating first-in-human clinical trial initiation while p…
Read the full FDA Biologics & Clinical Pipeline brief →FDA grants first-ever approval for a gene therapy targeting pediatric Sanfilippo syndrome type A
The FDA approved Fayuvi (rebisufligene etisparvovec-hopf) on September 17, 2026, as the first treatment for pediatric patients with mucopolysaccharidosis type IIIA. This is the first authorized gene therapy for this rare…
Read the full FDA Biologics & Clinical Pipeline brief →FDA issues guidance on buffy coat blood component manufacturing systems for device developers
FDA's Center for Biologics Evaluation and Research issued guidance in September 2026 establishing development and submission requirements for blood collection, processing, and storage systems used in buffy coat manufactu…
Read the full FDA Biologics & Clinical Pipeline brief →FDA issues draft guidance establishing credibility framework for AI models used in drug and biologics regulatory submissions
On September 1, 2026, the FDA released draft guidance setting out recommendations for AI models intended to support regulatory decisions on drug and biological product safety, effectiveness, and quality. Sponsors must sa…
Read the full FDA Biologics & Clinical Pipeline brief →FDA grants accelerated approval to Genglycos as first-ever treatment for glycogen storage disease type Ia
On August 19, 2026, the FDA granted accelerated approval to Genglycos (pariglasgene brecaparvovec-opnr) for patients aged 8 years and older with glycogen storage disease type Ia — the first authorized therapy for this co…
Read the full FDA Biologics & Clinical Pipeline brief →FDA CBER issues draft guidance on potency assessment for active immunotherapy products under docket FDA-2026-D-8561
FDA's Center for Biologics Evaluation and Research issued draft guidance on August 19, 2026 addressing potency assessment for active immunotherapy products, including cellular and gene therapy. The guidance presents FAQs…
Read the full FDA Biologics & Clinical Pipeline brief →FDA maintains approval of CYFENDUS anthrax post-exposure prophylactic vaccine for adults 18 through 65
The FDA product page for CYFENDUS confirms its approved indication as a post-exposure prophylactic vaccine for suspected or confirmed Bacillus anthracis exposure in persons aged 18 through 65, administered alongside a re…
Read the full FDA Biologics & Clinical Pipeline brief →FDA grants accelerated approval to Tudriqev for treatment-resistant advanced melanoma
The FDA granted accelerated approval on August 6, 2026 to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral therapy. The approval covers adult patients with advanced, refractory melanoma w…
Read the full FDA Biologics & Clinical Pipeline brief →FDA launches Expedited IND Pilot with rolling review and qualified research institution partnerships to accelerate Phase 1 trial initiation
FDA's Center for Biologics Evaluation and Research announced a structural reform of the Investigational New Drug process on August 5, 2026. The Expedited IND Pilot introduces rolling, component-by-component submission, Q…
Read the full FDA Biologics & Clinical Pipeline brief →FDA grants first U.S. license for a freeze-dried plasma product, Ezplaz, for adult transfusion use
FDA licensed Ezplaz Freeze Dried Plasma on July 29, 2026 — the first freeze-dried plasma product to receive U.S. market authorization. The license restricts Ezplaz to adult patients requiring plasma transfusion when othe…
Read the full FDA Biologics & Clinical Pipeline brief →FDA maintains approved labeling page for Gammaplex 5% and 10% intravenous immunoglobulin products
On July 17, 2026, the FDA's Center for Biologics Evaluation and Research published or updated its approved blood products page for Gammaplex 5% and 10%. The page confirms approved indications for primary humoral immunode…
Read the full FDA Biologics & Clinical Pipeline brief →FDA grants full approval to ALYGLO for primary humoral immunodeficiency in adults
The FDA approved ALYGLO, an intravenous immune globulin product, for the treatment of primary humoral immunodeficiency in adults, with the approval posted July 17, 2026. This action adds a new licensed biological product…
Read the full FDA Biologics & Clinical Pipeline brief →FDA issues Ebola donor eligibility guidance for all HCT/P establishments nationwide
On July 16, 2026, the FDA issued a safety communication directing human cell, tissue, and cellular and tissue-based product (HCT/P) establishments on Ebola disease considerations for donor eligibility determinations. The…
Read the full FDA Biologics & Clinical Pipeline brief →FDA grants first-ever approval for a chikungunya virus vaccine for adults 18 and older
The FDA has approved Ixchiq, a live attenuated chikungunya vaccine developed by Valneva — the first licensed vaccine for chikungunya virus disease in the United States. This approval creates a new licensed product catego…
Read the full FDA Biologics & Clinical Pipeline brief →FDA Biologics & Clinical Pipeline release pending Cresthaven Analytics full analysis: Procleix Ultrio Assay
FDA Biologics & Clinical Pipeline published a regulatory release titled 'Procleix Ultrio Assay'. Cresthaven Analytics' full intelligence brief is pending re-analysis; see the source link below for the complete primary te…
Read the full FDA Biologics & Clinical Pipeline brief →FDA licenses MD Anderson Cord Blood Bank HPC cord blood product for unrelated donor hematopoietic transplantation
The FDA has issued a biologics license to the MD Anderson Cord Blood Bank for a hematopoietic progenitor cell cord blood product indicated for unrelated donor transplantation with an appropriate preparative regimen. The …
Read the full FDA Biologics & Clinical Pipeline brief →FDA updates product approval record for Procleix Ultrio Plus Assays covering donor screening indications
On July 8, 2026, the FDA posted updated approval information for the Procleix Ultrio Plus Assay. The record covers screening of organ donors using beating-heart specimens, cadaveric donor blood specimens, and individual …
Read the full FDA Biologics & Clinical Pipeline brief →
Get every FDA Biologics & Clinical Pipeline brief delivered the day it lands
From $149/month
Cresthaven Analytics monitors FDA CBER continuously, applying institutional materiality scoring to every release. Subscribers receive structured briefs via email, portal, and (Professional tier and above) real-time alerts.
View all tiers →